Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript

2025-03-18 15:01:24 ET

Renalytix Plc (RNLXY)

Q2 2025 Earnings Conference Call

March 18, 2025, 10:00 AM ET

Company Participants

Julian Baines - Executive Chairman

Fergus Fleming - Chief Technology Officer

James McCullough - Co-Founder and Chief Executive Officer

Conference Call Participants

Presentation

Operator

Good afternoon, and welcome to Renalytix Investor Presentation. [Operator Instructions] We are joined by Renalytix management team.

I would now like to hand you over to Executive Chairman, Julian Baines, to begin the presentation.

Julian Baines

Good afternoon, everyone. Thank you for joining the Renalytix presentation half year report. I'm joined by our CTO, Fergus Fleming. And in the U.S., James McCullough, the CEO of the company, is also online.

For those of you who are new to the story, I don't know how many online are, Renalytix was formed out of a spinout of EKF. EKF in 2017 had two biomarkers called sTNFR1 and sTNFR2, which were licensed out of Joslin Diabetes Institute in the United States. These biomarkers would show that if you're a diabetic, it would indicate whether you are likely to go on to get end-stage renal disease or diabetic kidney disease.

Many years ago, that would have been a so what test, but these days, this is a very valuable -- these are very valuable biomarkers because they will tell you if you're going to go on to get end-stage renal disease and one of the biggest problems in society today is kidney dialysis.

Our test is so important to the kidney market that by utilizing this test, we can actually keep people off dialysis because if we refer the right patients for the right drugs, then they can use drugs such as SGLT2 inhibitors to keep them off dialysis, which is one of the biggest and most costly interventions in diagnostics today. And to keep people off dialysis is really important.

In my opinion, this is one of the most important tests I've ever been involved in. And not only does it show massive patient advantage in patient care, it also reduces the cost to society because kidney dialysis in the U.S. alone cost $90 billion a year, very invasive and very uncomfortable, and this improves patient outcome considerably....

Read the full article on Seeking Alpha

For further details see: